{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-187733","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2025-08-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.828404+00:00","generated_at":"2026-05-17T10:11:16.608672+00:00","sec_items":["8.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst settles Lupin patent litigation; generic FIRDAPSE launch no earlier than Feb 2035","bullets":["Lupin granted license to market generic FIRDAPSE beginning February 25, 2035, if FDA-approved.","All ongoing patent litigation between Catalyst/SERB and Lupin in New Jersey terminated.","Prior settlements with Teva and Inventia for FIRDAPSE generics already in place.","Pending patent litigation against Hetero for FIRDAPSE's Orange Book-listed patents continues.","Settlement will be submitted to FTC and DOJ for review as required."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-187733","json":"https://secwatch.observer/filing/0001193125-25-187733.json","markdown":"https://secwatch.observer/filing/0001193125-25-187733.md","text":"https://secwatch.observer/filing/0001193125-25-187733.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/0001193125-25-187733-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312525187733/d915025d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:11:16.608672+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}